good Thanks, everyone. Vince and morning,
tech of partnership, of leadership, Before known and of moment many associates. upcoming next to a for to company, is and I X, med thank Under the retirement the laying wisdom. him respected a years his like his also to Slide to and Vince deep BD culture his on phase congratulate for top has commitment CEO I'd BD purpose, transformed our and for development into move as five Vince's foundation our Vince of friendship our take leading growth. our
an understatement that say you'll I of missed all by to think it's us. be
partnership I'd also as BD like to to creation, growth remaining and he core I with values. look through committed next his BD’s guides to my and its value purpose Tom forward of appointment. while phase congratulate continued Tom on
and the as revenue on year. total the our X, as Fourth comparable revenues fourth X.X% moving to quarter quarter Slide key highlights grew Now results, I'll on basis. the financial neutral review currency and a for EPS quarter well
the in on growth a acceleration the color segment quarter half I of take in by through expectations you provide was when for results fiscal the geography. quarter revenue and revenue line and fourth year. I'll growth second broad-based in continued more our moment fourth Our with
on Fourth EPS prior or currency XX% $X.XX year, basis. XX.X% over the quarter growing neutral was adjusted a
approximately the for year. For grew neutral from would growth for X.X% a currency Adjusting basis. comparable revenues DCBs, have impact the X.X% on been the total revenue year, full
also XXXX. fiscal We in margins our expanded
in driven drove points margin neutral XXX expansion our of on an a XX.X% of quarter fiscal model operating leverage currency synergies. The of underlying XXXX, in basis, cost the expanded operating basis where business in million approximately On we is margins by results part a basis $XXX XXX the points realization fourth in Bard evident during basis.
more faced EPS neutral on remarks. EPS driven strong provide by which operating year of was XXXX color we growth the fiscal grew basis. notable year. headwinds currency X.X% a XX.X% later performance, Growth the mitigated Full I'll my in on adjusted $XX.XX throughout or
$XXX to and $X continued fiscal full quarter, paying debt during also delever of the year. for fourth down the We approximately billion million
our result, As times December to declined three the as a commitment to our ending leverage XXXX. years delever over gross We achieve XX. times to X.X below September X on track remain ratio of
record our dividend pleased Fiscal of dividend. increasing have very an delivering marked increases. also are we consecutive Additionally, XXXX to year of our continued longstanding XXth
revenue segment X.X% Medical Now to moving our Slide fourth the I in BD grew quarter on full Medical for and X, fiscal revenues growth. the review will X.X% year.
As Management expected, segment gains Systems. the Pharmaceutical share momentum Medication in strength continued by fourth was and Solutions quarter driven in Medical performance ongoing and in
Growth was included that diabetes a in large by Medication Delivery leading in strength quarter. Vascular Solutions Access Vascular Care markets and the care portfolios. in reflects Performance emerging in particularly tender our driven
BD fiscal the year which Now Systems. quarter in turning and drove by the XX our driven Revenue BD growth double-digit our with fourth Slide increased growth of for for Strength quarter units. continued Sciences the microbiology and was performance and fourth solutions Revenues Diagnostic at X.X% ID/AST in Systems Biosciences end platforms strong the culture in full well Life X.X% high as MAX, molecular guidance in as to range. Diagnostic in segment. our was and in growth blood the in
growth we the Preanalytical research sets. blood in to for Growth prior reflects as research as to a Systems our comparison in button when push meet and brought collection instruments well sales, was globally on strong capacity additional reagents. Biosciences year clinical tough demand
in and trend and BD year. quarter have reduction quarter, approximately with we Revenues seeing to for the fiscal full letter. been DCB-related X.X% FDA consistent results sales, X.X% XX% turning which segment. Now the the Slide Interventional is of budgeted a included the BDI's versus increased our fourth since XX fourth the originally
continue we our contracted, maintain While leading position. share and the is stable to market
would Excluding BDI have DCB grown the in segment the the revenues quarter. in fourth impact, low-double-digits
continued Intervention Our as to well. products overall Venovo the revenues in Covera grew in perform our solidly Peripheral extremely mid-single-digits WavelinQ, and
in growth the impact, quarter fourth been DCB PI low-double-digits. would also Excluding revenue have the in
in in Surgery reflect X.X% Progel the in strong ramp, we to in continue strength in benefit strength Prevention our and Europe U.S. as the see quarter revenue Infection continue growth from ongoing Biosurgery sales and where Biosurgery in performance revenue investments Hemostats. synergy Fourth of global to
strength by driven Care to as be Revenue our growth in as of continued in well Urology X.X% and business. acute Targeted continues urology Management Critical Temperature
By quarter, Slide in X.X% both in was revenues. fourth all Now markets driven broad-based moving the and grew Europe. performance geographic revenues three the XX, segments. and U.S. on to by our in strength Developed strong geography,
markets high-single-digit growth the For the broader for full quarter year grew X.X% developed fiscal markets region, quarter the fiscal and in fourth driven in the by Growth revenues double-digit year. full in X.X%. Pacific and Emerging Asia EMA. China and was growth grew
anticipated lower process. saw Growth we is annual pressure as in purchasing in than portfolio. in more provinces adopted volume-based in within in medical devices certain China the we some MDS was pricing late in fourth being the quarter new tender This of the basic our related to quarter the
single-digit and double-digit in year in XXXX, high-single-digit the ahead growth Sciences BD Medical fiscal Looking to the expect BD driven China, segment. in segments by Life and we growth Interventional growth
recaps which income the quarter XX, Slide to fourth statement. Turning
X.X% in quarter on strong As discussed, basis. revenues the a was comparable growing
Moving Gross strong DCB raw margin continuous pressure and by Currency margin as sales X% XX.X%. grew a and capture. more synergy down was the was headwinds P&L, anticipated, year-over-year. revenue improvement from growth, approximately than abated gross offset accelerated and materials profit lower
XX%. our spending reflects continued disciplined revenues SSG&A SSG&A as a percentage percentage cost achievement synergies. revenue R&D of as Bard of well X.X%. of as a was was as
model. neutral leverage operating operating a fiscal full the R&D the XXX points, the points margins commitment XXX our Fourth continued reflecting in to billion innovation. invested which For to-date, margins our highest year, quarter basis $X we adjusted drive quarterly are or basis XX.X% of in increasing currency on basis, reflects
in the Our XX% with bringing tax range. the guidance was XX.X%, our tax to in lower rate end quarter full of line our year rate
expected, the $XX As we million quarter. dividends paid preferred of in
of As XXXX. a reminder, the preferred shares May will in convert
share currency discussed, $X.XX on year, XX% of basis. adjusted prior a per neutral As versus and previously grew earnings the XX.X%
and fourth our operating to profit for the quarter. Now, Slide turning gross XX and margins
strong the previously XX.X% quarter growth fourth XX.X% discussed, As was margins in at and respectively. in operating
margin our For in margins margins on operating the expanded and neutral full with fiscal year, points basis we basis. XX Operating delivered ranges. line currency gross a guidance
to basis This back Looking proud ability strong we're expansion points execution have period, over over operating six continuous to last delivered improvement. the neutral years. currency a drive demonstrates and multi-year margin our XXX of
fiscal Now XXXX. XXXX moving drove Revenue to on Slide our performance growth combined in fiscal underlying XX EPS strong XX.X% growth. operating solid and EPS with growth of
is the May. FX P&L of since our the you currency we earnings May, EPS As were call headwinds, in we what divestitures our we able the to that sharing impact and in expectations back Since continued were mitigate with the line offset result, to the a materialized have been FX and of year. pressures able additional from deliver over to pressure with and and $XX.XX. This half
year to on fiscal full and Moving XXXX revenue Slide XX guidance. our
X.X% expect on growth We X% revenue currency to basis. neutral comparable a of
from point FDA we for sales, by DCB an of XX includes impact an the certain process MDS the be points guidance until pricing, the primarily XX fiscal basic revenue anniversary expected impact to estimated year-over-year impact year. the as towards Our lower of basis middle the as and the letter are well estimated basis driven from products, China which
of growth phasing to first a year the below the year growth be first XXX revenue perspective, guidance fiscal in From range, we basis the X% driven revenue of approximately quarter expect by full X%. to half points
upgrades including optimization. improvements Pump we business, some In to planning our software, to our Alaris to and prioritization make MMS are alarm
of balance the upgrades, the We and possibility are timing the fiscal software move This the QX bundling FDA them with expected these to from of with to of the is of year. release. in version about some discussions implementation sales the new timing of
we full will by By DCBs. also grow segment, quarter to revenues first and the pricing and BD Medical year, be X% for between the MMS, X%. expect impacted Beyond
X%. Sciences to Life to Interventional between BD grow X%. expect BD and we We between revenues and grow X% And revenues the expect X%
in to developed Similar markets. X.X% growth and previously growth to high-single-digit we diversified We strength across to as product by markets, be base driven EMA. all X% expect in segments high-single-digit recent emerging and anticipate XXXX. growth emerging expect driven a strength of we three fiscal developed fiscal China, discussed, XXXX, and In growth by around with launches both in market revenue in
Slide This to the EPS fiscal XXXX growth performance the XX.X% breaching XX%. of operating help the of EPS $XX.XX, left guidance. mitigate XX that of tariffs on is to to us and from the royalty, headwinds and chart, underlying strong high FX. teens will expiration of adjusted expect moving EPS our side the Gore XXXX fiscal growing off Now on of Starting we
As reminder, XXXX headwind the in size X fiscal original our point a to in in royalty deal end of a and toward Gore percentage XXXX. from expired view, the model increased growth resulting fiscal
are This to expected minimize our partners of approximately X to percentage actively by to of rate neutral XXXX. growth Currency which X.X% currency we a exchange dollar assumes company. XX% about be X.X% fiscal is to unfavorable of to $XX.XX, work the X.X a impact to and in continue deliver expected impact growth we the represents to point EPS points X% Tariffs of a euro headwind $XX.XX adjusted and to to with percentage $X.XX. to All-in, basis. on expect
absence phasing a revenue growth, anticipated expected royalty, lower of the quarter foreign are $X.XX. combined EPS currency of to first first result From in with the impact perspective, in $X.XX negative of Gore to translation the quarter
million continue We in to to $XXX XXXX. expect cost fiscal synergies year achieve approximately in
over million committed $XXX are annualized the cost deal We three-year realizing synergies period. in to fully
On to a due as to This performance, XX%. capture. percentage revenue is headwind approximately the the a currency the fiscal basis underlying Adjusted between be revenue reflects profit turning to balance synergy cost strong of for points. XXX X% year to Slide is expected full year for I'd including XX, our walk and is total Now of a XX% gross to basis, XXXX. growth X.X%. be expected approximately guidance like This expectations through to reported of
XX Adjusted compared points continued discipline. our basis by XX% cost fiscal SSG&A is of points an is improvement our the to to expected sales. business XX.X% is and approximately to and model This of XXX driven be to leverage basis in XXXX
which in We to in R&D and expect and in continued products to X.X% approximately XXXX. billion with X% reflects year revenues, platforms. to is $X invest invest represents commitment our of line This new fiscal
expansion expect As basis, operating be the and items XX% detailed, currency revenues. XXX a operating expected approximately strong I margin between to basis just a points. we of margin XX% of result On is neutral of
be our and between expect rate XX%. We tax XX% to
XXXX, For share adjusted shares. our XXX diluted average be fiscal anticipate fully we to approximately year count million
purposes, like reflects conversion modeling shares I'd approximately May $XX The deduction million For for will convert The be of dividends. neutral you dividend to time the EPS. the about net income in remind fiscal XXXX, which at that preferred will paid. preferred final XXXX of of preferred is
Cash Capital with be $X.X to flow billion expected million billion be operating are cash XXXX. is and $X billion. expenditures expected fiscal in about of strong to year between $XXX to flow $X.X
In the across summary, excited business. our deliver on will that I'm commitments have year we And in about I'm beyond. and XXXX our momentum fiscal confident we
the like back I'd to portfolio. provide will you update product turn who Vince, call on over to Now, our an with
